EW INVESTORS: Robbins LLP Reminds Investors of the Pending Lead Plaintiff Deadline in the Edwards Lifesciences Corporation Class Action

Core Viewpoint - A class action lawsuit has been filed against Edwards Lifesciences Corporation for allegedly misleading investors about the growth of its Transcatheter Aortic Valve Replacement (TAVR) platform during the specified period [1][2]. Allegations - The lawsuit claims that Edwards Lifesciences provided overly positive statements regarding TAVR's growth while concealing material adverse facts about its true performance [2]. - The company is accused of overestimating the treatment rate population and the commitment of hospitals to TAVR procedures compared to newer alternatives [2]. Financial Impact - On July 24, 2024, Edwards reported disappointing second-quarter financial results and reduced its revenue guidance for the TAVR platform for the full fiscal year 2024 [3]. - The company attributed the TAVR setback to the growth of structural heart therapies affecting hospital workflows [3]. - Following the announcement, Edwards' stock price fell from $86.95 to $59.70, a decline of approximately 31.34% [3]. Legal Proceedings - Shareholders interested in participating in the class action must submit their application by December 13, 2024, to serve as lead plaintiff [4]. - Participation in the case is not required to be eligible for recovery as an absent class member [4]. Company Background - Robbins LLP, the law firm handling the case, has a history of litigating securities class actions and has recovered over $1 billion for shareholders since its inception [5].